
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is expected to have a relatively easy path to regulatory approval thanks to a recent FDA guidance that aligns with the company's phase 3 trial design. The company's financials are strong, with a significant amount of cash on hand and a positive outlook for peak revenues of $3.8 billion in 2037. The company's drug, COMP360, has shown strong potential in clinical trials and is expected to have significant demand from prescribers, with 90% indicating they would prescribe it within the first year of availability. The stock's currently undervalued and we expect a $21 price target, which is based on a discounted cash flow analysis and includes credit for the company's potential expansion into treating PTSD.
Bears say
Compass Pathways is currently overvalued with a total firm value of $8.8 billion, based on a discounted cash flow methodology. This is mainly due to the high probability of success assigned for its treatment of treatment-resistant depression and PTSD, and the 12% discount rate used to calculate cash flows. However, there are numerous risks, such as clinical development and competitor risks, as well as regulatory and commercialization risks, that could affect the company's ability to achieve its price target of $65.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares